CERo Therapeutics Q3 2025 Earnings Results & Report

CERo Therapeutics EPS Results

• Actual EPS: -$9.10
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

CERo Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

CERo Therapeutics (NASDAQ:CERO) is a clinical-stage biotechnology company developing engineered cell therapies for the treatment of cancer. The company focuses on therapies designed to combine the tumor-targeting capabilities of T cells with the engulfing, or phagocytic, activity typically associated with cells of the innate immune system.

CERo’s technology platform is intended to create “CER-T” cells that can recognize and attack malignant cells through multiple mechanisms. Its research and development programs are aimed at hematologic cancers and potentially solid tumors, with lead development efforts focused on acute myeloid leukemia and other difficult-to-treat blood cancers.

The company’s lead investigational program, CER-1236, is being developed as an engineered cell therapy for patients with relapsed or refractory disease. Like other early-stage biotechnology programs, CERo’s candidates remain subject to clinical testing and regulatory review, and their safety and effectiveness have not been established for general use.

CERo Therapeutics became a publicly traded company through a business combination with Phoenix Biotech Acquisition Corp. The company is based in the United States and conducts its development activities through its biotechnology and cell-therapy operations.